
Keywords: prostatic neoplasms; high-intensity focused ultrasound ablation; registries; patient outcome assessment; biomedical technology; CRN; coordinated registry network; EPIC-26; Expanded Prostate Cancer Index Composite-26; FDA; Food and Drug Administration; HIF